Head of Investor Relations
Acadia Pharmaceuticals Inc (ACAD)Head of Investor Relations
Halozyme Therapeutics, Inc. (HALO)Equibles does not estimate personal net worth.
Get an email with a short summary when Acadia Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get ACAD alertsAl Kildani is recorded as Head of Investor Relations at Acadia Pharmaceuticals Inc (ACAD) and Head of Investor Relations at Halozyme Therapeutics, Inc. (HALO). Al Kildani has spoken on 10 earnings calls and 1 other investor event across 2 companies, most recently for Acadia Pharmaceuticals Inc on November 4, 2026. Those appearances were for Acadia Pharmaceuticals Inc (ACAD) and Halozyme Therapeutics, Inc. (HALO). Acadia Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Halozyme Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Acadia Pharmaceuticals Inc includes Catherine Owen Adams (CEO and Board Member), Stephen R. Biggar (Chairman and Board Member), Mark C. Schneyer (CFO) and 7 others.
“Good afternoon, and thank you for joining us on today's call to discuss Acadia's third quarter 2026 financial results.”
“Joining me on the call today from Acadia are Catherine Owen-Adams, our Chief Executive Officer, who will provide some opening remarks, followed by Tom Garner, our Chief Commercial Officer, who will discuss our commercial brands, Dayview and New Plazid.”
“Good afternoon, and thank you for joining us on today's call to discuss ACADIA's second quarter 2025 financial results.”
“Good afternoon, and thank you for joining us on today's call to discuss ACADIA's fourth quarter and full year 2024 earnings.”
Biotechnology · Healthcare
Head of Investor Relations
Biotechnology · Healthcare
Head of Investor Relations
